Contact Us

    Contact Us

    Axtria Inc. 300
    Connell Drive, 5th & 6th Floor,
    Berkeley Heights, NJ 07922
    United States

    +1-877-929-8742
    connect@axtria.com


    Copyright © 2023 Axtria. All Rights Reserved.

    Axtria Cookie Policy & Privacy Statement.

    Contact Us

    All Insights Report The Inflation Reduction Act and Its Implications on Real-World Evidence

    The Inflation Reduction Act and Its Implications on Real-World Evidence

    Contact Us
    RWE, HEOR & Evidence Synthesis

    The Inflation Reduction Act and Its Implications on Real-World Evidence

    Axtria's POV discusses the Inflation Reduction Act (IRA), passed in August 2022, which targets reducing prescription drug prices for Medicare beneficiaries in the United States (US). The POV highlights the implications of IRA on real-world evidence (RWE).

    Download Report
    The Inflation Reduction Act and Its Implications on Real-World Evidence

    The Inflation Reduction Act (IRA), passed in August 2022, targets reducing prescription drug prices for Medicare beneficiaries in the US. It introduces three major reforms:

    • Medicare Part D Changes: This affects how prescription drugs are covered under Medicare Part D.

    • Inflationary Caps in Medicare Part B: Sets limits on price increases for Medicare Part B services.

    • Medicare Price Negotiation: Allows Medicare to negotiate drug prices directly, impacting how pharmaceutical companies present evidence.

    The Medicare Drug Pricing Negotiation Program (DPNP) establishes maximum fair price (MFP) guidelines for specific drugs, starting with ten drugs in 2026. Pharmaceutical companies must collect robust RWE to support efficacy, safety, and economic impact for effective price negotiations. The sponsor’s proficiency in data analysis is crucial for handling quick turnarounds of RWE. To secure favorable negotiated prices, manufacturers need robust evidence highlighting how the treatment addresses an unmet medical need. By applying innovative methods like causal inference to large real-world databases, we can gain valuable insights into comparative long-term benefits of multiple competing interventions. The integrated approach to evidence generation, including RWE’s pivotal role, is crucial for informed pricing discussions. Axtria's POV discusses the implications of IRA on RWE.

    Contact us at connect@axtria.com with any questions.
    Drug pricing Inflation Reduction Act Medicare Real-World Evidence RWE & HEOR
    The Inflation Reduction Act and Its Implications on Real-World Evidence PDF Cover


    Download Report

    Complete the brief form to download the white paper

    Recommended insights

    The Inflation Reduction Act and Its Implications on RWE

    Article

    Evidence at the Forefront: Why Integrated Evidence Planning is Essential for Biopharma Innovation?

    Learn more
    The Inflation Reduction Act and Its Implications on RWE

    White Paper

    The Evolution and Future of Integrated Evidence Planning

    Learn more
    The Inflation Reduction Act and Its Implications on RWE

    Article

    Health Technology Assessment in a Multi-Indication Era

    Learn more